FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1655-1656 June 15, 1995 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

Edited by V. Craig Jordan. 278 pp. Madison, University of Wisconsin Press, 1994. $40. ISBN 0-299-14070-9.
By Helen Wiseman. 209 pp. New York, John Wiley, 1994. $52.95. ISBN 0-471-94316-9.

Tamoxifen is an extraordinary drug. Even those mesmerized by rational drug design will marvel at its usefulness. Originally identified for one purpose for which it turned out to be totally ineffective in humans (as a "morning after" pill), tamoxifen ultimately proved useful as the most frequently prescribed anticancer therapy in the world. Its history is fascinating and revealing. It is an effective antifertility agent, but the beneficiaries of this effect are mice, not humans. Discovered in 1962 by Dr. Arthur Walpole of ICI Pharmaceuticals, the drug first known as ICI 46,474 is a remarkable anticancer agent whose full effects are . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.